5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Overall survival by clinical stage according to the seventh edition (A)... | Download Scientific Diagram
Kaplan-Meier survival analyses of overall survival (A) and lung... | Download Scientific Diagram
Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients
EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
Stage 4 Lung Cancer Life Expectancy
Purpose
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
Cancers | Free Full-Text | Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre
Postoperative Survival of Lung Cancer Patients: Are There Predictors beyond TNM? | Anticancer Research
LIBTAYO® (cemiplimab-rwlc) Overall Survival Rate in Advanced NSCLC
Non-Small Cell Lung Cancer
Median survival for metastatic ALK+ lung cancer can be more than SIX YEARS! | Gray Connections
Many non-small cell lung cancer Medicare patients not staged according to guidelines, leading to higher mortality rates
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data